Chuck Ence - Dec 17, 2021 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
CA and Compliance Officer
Signature
/s/ Chuck Ence
Stock symbol
RLMD
Transactions as of
Dec 17, 2021
Transactions value $
$0
Form type
4
Date filed
5/26/2022, 06:39 PM
Next filing
Dec 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLMD Stock Option (right to buy) Award $0 +295K +130.23% $0.00 522K May 25, 2022 Common Stock 295K $19.03 Direct F1, F2
transaction RLMD Stock Option (right to buy) Award $0 +200K $0.00 200K May 25, 2022 Common Stock 200K $19.03 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.
F2 The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.
F3 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder ("MDD") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol.